InvestorsHub Logo
icon url

rosemountbomber

09/16/21 2:46 PM

#354681 RE: ggwpq #354674

GG, I like your proposition but have a few questions.

1. I can’t find what PFE gets out if the HLS deal ( I realize we think it is a test run)

2. I do remember the analyst estimating 2.4b for the EU, but what was KM talking about with his estimate of 1B?

3. Do you think PFE would agree to a 50:50 split for covering all costs and expenses and work to sell in the EU?
icon url

sts66

09/17/21 3:45 PM

#354803 RE: ggwpq #354674

Forget the numbers, look at the big picture - what is AMRN if they partner with PFE in the EU? Basically a holding company unless they try to develop new drugs, which will be difficult even if they acquire one. I used to own a bio that sold off the sales rights for it's two approved drugs to fund a third drug and they ended up merging with someone else out of desperation, new company is a real penny stock, currently 4 cents/shr - 3rd drug didn't pan out. Before they went after that 3rd drug they just distributed cash flow to shareholders for 2 yrs - were a holding company.